Table 4.
Significant factor associations to the answers to the structured interview question 9.
| Factor | Level | N (row %) | p-value | ||||
|---|---|---|---|---|---|---|---|
| N | COVID-19 | Oncological Disease | Both equally | missing | |||
| Previous Surgery/Pulmonary RT | No | 83 | 11 (13.3) | 48 (57.8) | 16 (19.3) | 8 (9.6) | |
| Yes | 73 | 22 (30.1) | 41 (56.2) | 10 (13.7) | 0 | 0.003 | |
| Therapy | Intravenousa | 83 | 5 (10.4) | 30 (62.5) | 11 (27.1) | 2 (4.2) | |
| TKI | 55 | 14 (25.5) | 35 (63.6) | 4 (7.3) | 2 (3.6) | 0.02 | |
| Months from cancer diagnosis | ≤3 | 28 | 2 (7.1) | 20 (71.4) | 5 (17.9) | 1 (3.6) | |
| (3,12] | 32 | 4 (12.5) | 14 (43.8) | 10 (31.3) | 4 (12.5) | ||
| >12 | 96 | 27 (28.1) | 55 (57.3) | 11 (11.5) | 3 (3.1) | 0.006 | |
a
Intravenous: CT, CT+IO, CT+RT, IO.
TKI, tyrosine kinase inhibitor; CT, chemotherapy; IO, immunotherapy; RT, radiotherapy.